BMO Capital analyst Keith Bachman maintains Dynatrace (NYSE:DT) with a Outperform and raises the price target from $42 to $49.
The Latest Analyst Ratings for United Therapeutics
Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…